Sign inJoin waitlistJoin the waitlist

Omid Hamid

Chief of Translational Research and Immuno-Oncology · Cedars-Sinai Cancer at The Angeles Clinic and Research Institute

Credentials: · ·

History

Translational Research and Immuno-Oncology Division · Cedars-Sinai Cancer at The Angeles Clinic and Research Institute
Present
Cedars-Sinai
Present

Hematology and Medical Oncology
Internal Medicine

Research

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
New England Journal of Medicine · 2012 · 6,533 citations
Pembrolizumab for the treatment of non-small-cell lung cancer
New England Journal of Medicine · 2015 · 5,237 citations
Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2015 · 4,750 citations

JW
Jeffrey Weber
37 papers
Adil Daud
34 papers
Stephen Hodi
34 papers
Antoni Ribas
31 papers
Igor Puzanov
30 papers
Jedd Wolchok
23 papers
KL
Karl Lewis
23 papers
RC
Richard Carvajal
22 papers
Inderjit Mehmi
19 papers
SO
Steven O'Day
19 papers
Tara Mitchell
19 papers
Anna Pavlick
18 papers

Clinical trials

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Principal investigator · Recruiting · Phase 1, Phase 2
Georgiamune Inc
2023–2026
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Principal investigator · Active not recruiting · Phase 1, Phase 2
Treadwell Therapeutics, Inc
2020–2025
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Principal investigator · Completed · Phase 1, Phase 2
MedImmune LLC
2014–2020
SMP-3124LP in Adults With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Sumitomo Pharma America, Inc.
2024–2029